Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-986256
Afimetoran · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Afimetoran: Dose 1 | EXPERIMENTAL | - |
| Afimetoran: Dose 2 | EXPERIMENTAL | - |
| Afimetoran: Dose 3 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| BMS-986256 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Afimetoran | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| BMS-986256 | DRUG | Specified Dose on Specified Days |
| BMS-986256 Placebo | OTHER | Specified Dose on Specified Days |
Inclusion Criteria: * Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit * Test positive, as determined by the central laboratory, for at least one of the following...
Top 20 of 34 competitors
Afimetoran is being studied for the treatment of active systemic lupus erythematosus (SLE), an autoimmune disease. It is an investigational oral small molecule and has not been approved for any indication. Bristol-Myers Squibb is evaluating it in adults with active SLE in a Phase 2 clinical trial.
Afimetoran targets TLR7 and TLR8, two toll-like receptors involved in immune signaling. It acts as an inhibitor of these receptors. By blocking TLR7 and TLR8, the drug is designed to dampen the inflammatory immune responses that drive systemic lupus erythematosus. This mechanism is being tested in a Phase 2 study.
Afimetoran is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is running a Phase 2 clinical trial of the drug in patients with active systemic lupus erythematosus. No other developer or partnership for afimetoran is disclosed in the available information.
Afimetoran is in Phase 2 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is evaluating its efficacy and safety compared with placebo in participants with active systemic lupus erythematosus.
Afimetoran is being studied in one clinical trial, NCT04895696, titled a study evaluating the efficacy and safety of afimetoran compared with placebo in participants with active systemic lupus erythematosus. The Phase 2 trial has enrolled 248 participants, is randomized, double-blind, and placebo-controlled, and is currently active but not recruiting.
Afimetoran is a distinct investigational small molecule developed by Bristol-Myers Squibb. It is not the same as any approved lupus therapy. It is identified by the ChEMBL ID CHEMBL4650329 and is being studied specifically as a TLR7 and TLR8 inhibitor for active systemic lupus erythematosus.